Wakamoto Pharmaceutical Co., Ltd.

Touru Oguma

Makoto Maeda

Hidekazu Suzuki

Hiroki Maruyama

Masanobu Takeuchi

Hiroe Suzuki

Satoshi Yamazaki

Kenji Endo

Masayoshi Goto

Toshie Takahashi

Yoshikazu Naito

Takahiro Wada

Katsuya Ohata

Toshio Kuroda

Yoshihiro Tsuriya

Terumasa Hashimoto

Tooru Abe

Kaei Nagoshi

Keiko Naito

Miyako Sasaki

Noriko Tahira

Reiko Hirata

Shinji Kageyama

Yoshiaki Ogasawara

Shigekatsu Kohno

Takao Shida

Yukiyoshi Yanagihara

Keiko Naitou

Miyako Fukushima

O/W emulsion composition for eye drops

Anti-inflammatory eye drop

Lyophilized pharmaceutical preparations capable of providing aqueous

A lipid emulsion which comprises (A) an oil component, (B) an emulsifying agent containing yolk lecithin and/or soybean lecithin, and (C) water, wherein the lipid emulsion further comprises citric acid or a pharmaceutically acceptable salt thereof and at least one member selected from the group consisting of methionine, phenylalanine, serine, histidine and pharmaceutically acceptable salts thereof, provided that it does not simultaneously contain methionine and phenylalanine. The addition of citric acid and histidine, methionine, phenylalanine and/or serine to a lipid emulsion containing natural lecithin as an emulsifying agent permits the prevention of change of color and formation of oil drops associated with the conventional natural lecithin-containing lipid emulsion due to the synergistic effect of the foregoing additives. The drug-containing lipid emulsion is also excellent in storage stability and thus the foregoing lipid emulsion can be applied to drugs such as injections, eye drops, nasal drops, lotions or liniments, inhalants and drugs for oral administration or cosmetics such as humectants.

Stable lipid emulsion

Aqueous drug composition having property of reversible thermosetting

An aqueous dispersion containing liposomes comprising yolk lecithin and/or soybean lecithin as lipids for forming liposomes wherein the dispersion contains a hydroxy acid and an amino acid, which hardly shows coloration, shows little leak of drugs encapsulated in the liposomes and is stable in a broad pH range.

Stable aqueous dispersions containing liposomes

5-(3-n-Butyloxalylaminophenyl) tetrazole having an excellent SRS-A release-inhibiting effect is used as an effective component for an anti-asthmatic agent, and a pharmaceutical preparation obtained by mixing the tetrazole with a specific dispersant such as polysorbate-80 in coexistence with a non-aqueous solvent shows high dissolubility and bioavailability.

Anti-asthmatic composition and process for preparing the same

Growing community of inventors

Tokyo, Japan

Touru Oguma